Irrimax

Irrimax Corporation, through its flagship product Irrisept, specializes in providing advanced wound irrigation solutions. The company operates in the healthcare sector, focusing on both the U.S. and international markets. Irrisept is a patented, self-contained jet lavage system that uses a low concentration of chlorhexidine gluconate (CHG) as a preservative. This product is designed to improve wound healing by effectively removing foreign materials and microorganisms from wounds while minimizing irritation. The primary clients include hospitals, clinics, and healthcare providers who require efficient and reliable wound care solutions. Irrimax's business model revolves around the sale of its proprietary irrigation systems to licensed physicians and healthcare institutions, generating revenue through direct sales and distribution partnerships. The company leverages its innovative technology to address the needs of the medical community, ensuring better patient outcomes and streamlined wound care processes.

Keywords: wound irrigation, jet lavage, antimicrobial, CHG, healthcare, hospitals, clinics, wound care, medical devices, Irrisept